Key clinical point: Compared with injectable therapies, newer disease-modifying therapies more effectively reduce clinical and radiologic activity in children with multiple sclerosis (MS).

Major finding: Escalation to a second-line therapy reduced the annualized relapse rate from 1.7 to 0.2.

Study details: A retrospective study of 103 patients with pediatric MS treated at seven centers between 2012 and 2018.

Disclosures: The study was conducted on behalf of the UK Childhood Inflammatory Demyelination Network. Dr. Abdel-Mannan had no relevant disclosures.